Anti-oxidized low-density lipoprotein antibody levels are associated with the development of type 2 diabetes mellitus.
BACKGROUND
Anti-oxidized low-density lipoprotein (LDL) antibodies are associated with the oxidative capacity of plasma, but whether they protect or promote diabetes is unknown. We undertook a prospective study to determine the predictive capacity of anti-oxidized LDL antibodies for the onset of type 2 diabetes mellitus (T2DM).


METHODS
We selected 391 non-diabetic women aged 18-65 years. The subjects were classified as being normal (oral glucose test tolerance normal, OGTT-N), or having impaired glucose tolerance (IGT), impaired fasting glucose (IFG) or T2DM according to their baseline glucose levels and after an OGTT. The same subjects were studied six years later. The levels of anti-oxidized LDL antibodies were classified as above or below the 50th percentile.


RESULTS
Of the women who were OGTT-N at the start of the study and who had anti-oxidized LDL antibody levels below the 50th percentile, only 65.1% were still OGTT-N after 6 years versus 79.5% of those who had anti-oxidized LDL antibody levels above the 50th percentile (P = 0.015). Women who had IGT or IFG at the start of the study whose anti-oxidized LDL antibody levels were below the 50th percentile had a relative risk of 9.79 (95% confidence interval, 1.40-68.45) of developing diabetes (P < 0.001). Logistic regression analysis showed that the variables predicting the development of a carbohydrate metabolism disorder in the women after 6 years were body mass index (P < 0.001) and the levels of anti-oxidized LDL antibodies (P = 0.042).


CONCLUSIONS
Levels of anti-oxidized LDL antibodies are independent predictors for the development of T2DM in women.
Endocrinology and Nutrition Service, Virgen de la Victoria Clinical Hospital, Malaga, Spain.
L
L
Garrido-Sánchez
F
F
Cardona
E
E
García-Fuentes
G
G
Rojo-Martínez
J M
JM
Gómez-Zumaquero
M J
MJ
Picón
F
F
Soriguer
F J
FJ
Tinahones
D000293:Adolescent; D000328:Adult; D000368:Aged; D000906:Antibodies / Q000032:analysis*; D001786:Blood Glucose / Q000378:metabolism; D003924:Diabetes Mellitus, Type 2 / Q000276:immunology*; D005260:Female; D005500:Follow-Up Studies; D005951:Glucose Tolerance Test; D006801:Humans; D008077:Lipoproteins, LDL / Q000276:immunology* / Q000378:metabolism; D008875:Middle Aged; D012307:Risk Factors
D000906:Antibodies; D001786:Blood Glucose; D008077:Lipoproteins, LDL; C099252:oxidized low density lipoprotein